Action Radial Research - RAD

Radial Research Corp (RAD) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

0,135

( - )

Prix Achat

0,095

Prix Vente

0,135

Volume échangé

0,00 Fourchette du Jour 0,00

0,005 Plage de 52 semaines 0,195

Cap du marché

375,815k

Clôture Veille

0,135

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

$ 10 029

Actions en circulation

2 783 818

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-2,84

Bénéfice par action (BPA)

-0,05

Chiffre d'affairess (LTM)

Bénéfice net (LTM)

-132,36k

Radial Research Corp. operates as a technology company in Canada. The company develops online and download technologies and services, including software, websites, and smartphone applications. Its projects include Zoompages, an e-commerce sales funnel content management system; The Commuter, a trip ... Radial Research Corp. operates as a technology company in Canada. The company develops online and download technologies and services, including software, websites, and smartphone applications. Its projects include Zoompages, an e-commerce sales funnel content management system; The Commuter, a trip planning application; Good Inc, a mobile application for pet donations; Rental Platform, a rent platform website and mobile application; and Trill Bank, a banking system. Radial Research Corp. was incorporated in 2017 and is based in Vancouver, Canada. Show more

Secteur

Technology

Industrie

Software & It Services

Site Web

radial-research.com

Siège social

Vancouver, Canada

Fondé

2026

Radial Research Corp est coté dans le secteur Technology de la Canadian Securities Exchange avec le ticker RAD. Le dernier cours de clôture d'Radial Research était de $0,14. Au cours de la dernière année, les actions de Radial Research ont été négociées dans une fourchette de prix de $ 0,005 à $ 0,195.

Radial Research compte actuellement 2 783 818 actions en circulation. La capitalisation boursière d'Radial Research est de $375 815,43 . Radial Research a un ratio cours/bénéfice (ratio PE) de -2.84.

Radiopharm Theranostics Reports Business Update

Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain...

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

177Lu-RAD202 demonstrated encouraging tumor uptake and a favorable safety profile in the lowest dose cohort ...

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

Interim data to date showed 90% concordance with MRI (the primary endpoint) Clinical trial readout (Primary...

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

SYDNEY, April 08, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or...

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in...

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission...

Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

90% of patients dosed with RAD 101 and evaluable at interim analysis achieved concordance with MRI imaging (the...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0.135	0.135	0.135	30	0.135	CS
4	-0.005	-3.57142857143	0.14	0.14	0.095	141	0.1280679	CS
12	0.045	50	0.09	0.195	0.085	1092	0.14149403	CS
26	0.13	2600	0.005	0.195	0.005	10445	0.03025673	CS
52	0.125	1250	0.01	0.195	0.005	17115	0.0133775	CS
156	0.115	575	0.02	0.195	0.005	6989	0.01334246	CS
260	0.055	68.75	0.08	0.195	0.005	5833	0.01706542	CS

RAD - Frequently Asked Questions (FAQ)

What is the current Radial Research Corp share price?

The current share price of Radial Research Corp is $ 0,135

How many Radial Research Corp shares are in issue?

Radial Research Corp has 2 783 818 shares in issue

What is the market cap of Radial Research Corp?

The market capitalisation of Radial Research Corp is CAD 375,82k

What is the 1 year trading range for Radial Research Corp share price?

Radial Research Corp has traded in the range of $ 0,005 to $ 0,195 during the past year

What is the PE ratio of Radial Research Corp?

The price to earnings ratio of Radial Research Corp is -2,84

What is the registered address of Radial Research Corp?

The registered address for Radial Research Corp is 890 West Pender Street, Vancouver, British Columbia, V6C 1J9

What is the Radial Research Corp website address?

The website address for Radial Research Corp is radial-research.com

Which industry sector does Radial Research Corp operate in?

Radial Research Corp operates in the Software & IT Services sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Radial Research Corp (RAD)

Radial Research Corp (RAD) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Radial Research Corp

RAD Dernières nouvelles

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)

Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates

RAD Increases Ownership in Radiopharm Ventures to 87.5%

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)

RAD - Frequently Asked Questions (FAQ)

RAD Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités